These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. Sannomiya M; Katsu H; Nakayama K Seishin Shinkeigaku Zasshi; 2003; 105(5):643-58. PubMed ID: 12875232 [TBL] [Abstract][Full Text] [Related]
48. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882 [TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593 [TBL] [Abstract][Full Text] [Related]
50. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167 [TBL] [Abstract][Full Text] [Related]
51. A syndrome of increased affect in response to risperidone among patients with schizophrenia. Ashleigh EA; Larsen PD Psychiatr Serv; 1998 Apr; 49(4):526-8. PubMed ID: 9550246 [TBL] [Abstract][Full Text] [Related]